Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3030477 | 0.99 | KCNH2 (0.73) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL3031673 | 0.96 | CYP2D6 (0.73) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL3637531 | 0.95 | CYP2D6 (0.74) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL3022619 | 0.95 | CYP2D6 (0.74) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL3025595 | 0.86 | CYP2D6 (0.74) | CYP2D6KCNH2PPARGPPARA | |
| Hydrochloric Acid SCHEMBL3031230 | 0.85 | KCNH2 (0.75) | CYP2D6KCNH2PPARGPPARA | |
| Evenamide SCHEMBL29389974 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2 | |
| Evenamide SCHEMBL3025285 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2 | |
| SCHEMBL3031057 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL3030424 | 0.83 | CYP2D6 (0.91) | CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155663-B1 | SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2017-11-29 | — | — | EP | claimed |
| US-9248116-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-02-02 | — | — | US | claimed |
| CN-101687773-B | Substituted 2- [2- (phenyl) ethylamino ] alkanamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARM SPA | 2014-07-30 | — | — | CN | claimed |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-31 | — | — | US | claimed |
| US-8519000-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-08-27 | — | — | US | claimed |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | claimed |
| EP-2155663-B1 | SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARM SPA (IT) | 2017-11-29 | — | — | EP | disclosed |
| US-9603832-B2 | Substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-9585869-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-9474738-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| US-9474739-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| US-9474737-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-10-25 | — | — | US | disclosed |
| US-9248116-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-02-02 | — | — | US | disclosed |
| CN-101687773-B | Substituted 2- [2- (phenyl) ethylamino ] alkanamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARM SPA | 2014-07-30 | — | — | CN | disclosed |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-31 | — | — | US | disclosed |
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-10-17 | — | — | US | disclosed |
| US-8519000-B2 | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-08-27 | — | — | US | disclosed |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | disclosed |
| EP-2155663-A1 | SUBSTITUTED 2- Ý2- (PHENYL) ETHYLAMINO¨ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151702-A1 | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274249-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CYP2D6 3287/4885KCNH2 174/4885PPARG 1141/4885 |
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CYP2D6 3284/4885KCNH2 169/4885PPARG 1119/4885 |
| US-20130289122-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CYP2D6 3287/4885KCNH2 174/4885PPARG 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.